Skip to content

Staple-line Reinforcement for Prevention of Pulmonary Air Leakage

Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00925444
Acronym
SPIRAL
Enrollment
380
Registered
2009-06-22
Start date
2009-06-30
Completion date
2013-03-31
Last updated
2013-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest Tubes, Lung Neoplasms, Pulmonary Surgical Procedures, Surgical Staplers, Tissue Adhesives

Keywords

Absorbable implants, Humans, Alginates, Pneumonectomy/methods, Pneumonectomy/instrumentation, Surgical Stapling, Thoracic surgery, Tissue Adhesives, Prospective studies

Brief summary

The aim of this study is to compare the efficacy of FORESEAL with stapling alone or associated with tissue sealant or glue in terms of air leakage duration after lung resection for cancer. Hypothesis: to show a significant difference of 1 day in the average duration of air leakage between the 2 groups with a standard deviation of 3 (α =0.05 and β=0.10).

Detailed description

Air leaks continue to be the most common complication after pulmonary resection even using a stapling device. Double chest tubes after lobectomy is a well established method for drainage of the pleural cavity to allow adequate expansion of the remaining lung. FORESEAL has been developed to reduce air leaks by buttressing the staple line. It is a absorbable vegetal biopolymer in the form of sleeves, CE marked and indicated for prevention of air leakage after pulmonary resection with stapling device. It acts as a suture reinforcement as well as a sealant thanks to its jellification. Sealants are also commonly used in addition to stapling to prevent air leakage. The aim of this study is to compare the efficacy of FORESEAL with stapling alone or associated with sealants. This is a multi centre, prospective controlled and randomised clinical study.

Interventions

DEVICEFOREseal

a pair of alginate sleeves for linear cutting staplers used in lung surgery

DEVICEStapling

Stapling alon or associated with sealants

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patient 18 years old or over. * Patient that undergoes a lobectomy or bilobectomy for lung cancer, * Patient presenting an incomplete fissure, requiring stapling of at least 50% of the fissure and/or an emphysematous lung at the fissure point, requiring stapling. * Patient that has signed the informed consent before the operation. * Patient that benefits from a social security regime.

Exclusion criteria

* Patient with history of thoracotomy on the side operated on. * Patient with severe pleural infection and/or infection of parenchyma. * Presence of air leakage after liberation of lung in cases of pleural symphysis. * Patient pregnant, giving birth or nursing. * Patient presenting a contra indication to the aerostatic products used. * Patient already participating in biomedical research.

Design outcomes

Primary

MeasureTime frame
Air leak (presence or absence of bubbles) will be assessed from T0: one hour after extubation, and then twice daily (morning and evening). The mean duration of post-operative air leakage will be calculated from T0 to the last day air leak observed.from T0 to the last day air leak observed

Secondary

MeasureTime frame
Incidence of patients presenting prolonged air leakage (lasting more than 5 days). Average duration of drainage Incidence of patients without any air leakage at 24 hours after surgery Post-operative complications Nature and costs of treatmentswithing the first one year after surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026